




(86) Date de dépôt PCT/PCT Filing Date: 2018/12/27
 (87) Date publication PCT/PCT Publication Date: 2019/10/31
 (45) Date de délivrance/Issue Date: 2023/09/19
 (85) Entrée phase nationale/National Entry: 2020/10/14
 (86) N° demande PCT/PCT Application No.: CN 2018/124247
 (87) N° publication PCT/PCT Publication No.: 2019/205700
 (30) Priorités/Priorities: 2018/04/27 (CN201810392676.8);
 2018/07/19 (CN201810797624.9)

(51) Cl.Int./Int.Cl. *A61K 9/00* (2006.01),
A61K 31/4152 (2006.01), *A61K 47/10* (2017.01),
A61K 47/26 (2006.01), *A61K 47/38* (2006.01),
A61K 9/20 (2006.01), *A61P 21/00* (2006.01),
A61P 25/00 (2006.01), *A61P 25/02* (2006.01),
A61P 9/10 (2006.01)

(72) Inventeurs/Inventors:
 WANG, YILONG, CN;
 WANG, YONGJUN, CN;
 ZHAO, XINGQUAN, CN;
 ZHANG, ANYUAN, CN

(73) Propriétaires/Owners:

(54) Titre : COMPOSITION PHARMACEUTIQUE D'EDARAVONE
 (54) Title: EDARAVONE PHARMACEUTICAL COMPOSITION



(57) Abrégé/Abstract:

Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration

(73) **Propriétaires(suite)/Owners(continued)**:BEIJING Tiantan Hospital, Capital Medical University, CN;
Nanjing Baixinyu Pharmaceutical Co. Ltd., CN

(74) **Agent**: BCF LLP

(57) **Abrégé(suite)/Abstract(continued)**:

preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.

(12) 按照专利合作条约所公布的国际申请

(19) 世界知识产权组织
国际局(43) 国际公布日
2019年10月31日 (31.10.2019)(10) 国际公布号
WO 2019/205700 A1

(51) 国际专利分类号:

A61K 9/00 (2006.01) A61K 31/4152 (2006.01)
 A61K 9/20 (2006.01) A61P 25/00 (2006.01)
 A61K 47/26 (2006.01) A61P 21/00 (2006.01)
 A61K 47/10 (2006.01) A61P 9/10 (2006.01)
 A61K 47/38 (2006.01) A61P 25/02 (2006.01)

(71) 申请人: 首都医科大学附属北京天坛医院 (BEIJING TIAN TAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY) [CN/CN]; 中国北京市丰台区南四环西路119号, Beijing 100070 (CN)。南京百鑫愉医药有限公司 (NANJING BAIXINYU PHARMACEUTICAL CO. LTD.) [CN/CN]; 中国江苏省南京市秦淮区御道街58-1号第二层, Jiangsu 210007 (CN)。

(21) 国际申请号: PCT/CN2018/124247

(22) 国际申请日: 2018年12月27日 (27.12.2018)

(25) 申请语言: 中文

(26) 公布语言: 中文

(30) 优先权:

201810392676.8 2018年4月27日 (27.04.2018) CN
 201810797624.9 2018年7月19日 (19.07.2018) CN

(72) 发明人: 王伊龙 (WANG, Yilong); 中国北京市丰台区南四环西路119号, Beijing 100070 (CN)。王拥军 (WANG, Yongjun); 中国北京市丰台区南四环西路119号, Beijing 100070 (CN)。赵性泉 (ZHAO, Xingquan); 中国北京市丰台区南四环西路119号, Beijing 100070 (CN)。张安元 (ZHANG,

(54) Title: EDARAVONE PHARMACEUTICAL COMPOSITION

(54) 发明名称: 依达拉奉药物组合物




图 1

AA DISSOLUTION CURVE
 BB CUMULATIVE DISSOLUTION (%)
 CC EMBODIMENT 1
 DD EMBODIMENT 2
 EE EMBODIMENT 3
 FF EMBODIMENT 4
 GG EMBODIMENT 5
 HH TIME (MIN.)

(57) Abstract: Disclosed in the present invention are an edaravone pharmaceutical composition and an application thereof as a sublingual preparation, the pharmaceutical composition containing edaravone or a salt thereof and mannitol. A sublingual administration preparation can avoid the first-pass effect of the liver, and samples feature good stability, convenience of transport and of use, among other advantages.

(57) 摘要: 本发明公开了一种依达拉奉药物组合物及其用作舌下制剂的用途, 其中所述药物组合物包含依达拉奉或其盐以及甘露醇。舌下给药制剂, 可以避免肝脏首过效应, 样品具有稳定性好、便于运输、使用方便等优点。

[见续页]

WO 2019/205700 A1 

Anyuan); 中国江苏省南京市秦淮区御道街
58-1号第二层, Jiangsu 210007 (CN)。

(74) 代理人: 北京集佳知识产权代理有限公司
(UNITALEN ATTORNEYS AT LAW); 中国北京
市朝阳区建国门外大街22号赛特广场
7层, Beijing 100004 (CN)。

(81) 指定国(除另有指明, 要求每一种可提供的国家
保护): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG,
BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU,
CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB,
GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS,
JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK,
LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX,
MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL,
PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL,
SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, ZA, ZM, ZW。

(84) 指定国(除另有指明, 要求每一种可提供的地区
保护): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ,
NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 欧亚 (AM,
AZ, BY, KG, KZ, RU, TJ, TM), 欧洲 (AL, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT,
RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)。

本国际公布:

— 包括国际检索报告(条约第21条(3))。

EDARAVONE PHARMACEUTICAL COMPOSITION


[0001] This application claims the priority of Chinese patent application No. 201810392676.8, filed with the Chinese Patent Office on April 27, 2018, titled as “Edaravone pharmaceutical composition”, and Chinese patent application No. 201810797624.9, filed with the Chinese Patent Office on July 19, 2018, titled as “Edaravone pharmaceutical composition”.

FIELD

[0002] The invention belongs to the field of medical technology and relates to a sublingual edaravone pharmaceutical composition and the use thereof.

BACKGROUND

[0003] Edaravone (chemical name: 3-methyl-1-phenyl-2-pyrazoline-5-one) is a cerebral nerve protective agent that has been marketed (Yakugaku Zasshi. 2004, 124(3): 99-111). Studies have shown that edaravone has antioxidant activity, which can significantly improve the symptoms of neurological deficits in cerebral ischemia-reperfusion animals, reduce the infarct size, reduce the degree of brain damage, alleviate cerebral edema, and inhibit lipid peroxidation in damaged brain tissue.



Edaravone

(Molecular formula $C_{10}H_{10}N_2O$, molecular weight 174.20)

[0004] Cerebrovascular disease, especially ischemic cerebrovascular disease, is an acute disease,

and it needs to be relieved quickly. Therefore, administration by injection is the preferred method of first aid. However, the application of intramuscular injection or intravenous injection is subject to certain medical restrictions due to its tendency to cause pain and irritation at the injection site, and the requirement for operation by medical professionals as well as injection supplies, etc.,
5 making it difficult to apply to patients with out-hospital onset.

[0005] Sublingual preparations are those directly absorbed by the sublingual mucosa. The sublingual mucosa has a large surface area and strong penetrating ability, and a large number of capillaries under the mucosa gather to the internal jugular vein and directly enter the blood circulation through the superior vena cava. After administration, the drug is quickly absorbed with
10 a rapid onset. The preparations are accurate in quantification and convenient of use, avoiding the first-pass effect of oral drugs. For unexpected cerebrovascular diseases, sublingual preparations, especially sublingual tablets, can greatly improve the convenience of drug administration and the compliance of clinical patients as compared to injections.

[0006] However, sublingual pharmaceutical compositions containing edaravone are not easy to
15 prepare. The inventor has found through experiments that many commonly used excipients are not suitable for preparing qualified sublingual preparations, or the performance (stability, release rate, etc.) of the prepared sublingual preparations is not satisfactory.

[0007] Therefore, there is still an urgent need for a sublingual pharmaceutical composition containing edaravone with satisfactory stability and/or release rate.

20

SUMMARY

[0008] The object of the present invention is to provide a sublingual pharmaceutical composition containing edaravone or a salt thereof as an active ingredient, which has satisfactory stability and/or release rate.

25 **[0009]** The inventors have unexpectedly discovered that some commonly used fillers, such as lactose, are not suitable for the formulation of the edaravone sublingual preparations. In the experiment, it was found that the edaravone preparation prepared with lactose as a filler performed

poorly in the stability test, causing problems such as color discoloration.

[0010] After further experiments, the inventor unexpectedly found that by using fillers excluding those easily cause color changes, such as using mannitol as a filler, in an edaravone pharmaceutical composition, the problems described above can be effectively solved and the edaravone pharmaceutical composition with satisfactory stability and/or release rate is obtained. Based on this finding, the present invention provides a pharmaceutical composition containing edaravone or a salt thereof.

[0011] The results of pharmacokinetic data showed that the pharmacokinetic parameters T_{max}, C_{max} and AUC of the edaravone pharmaceutical composition of the present invention administered sublingually and the edaravone injection administered by intravenous drip are almost the same, and this fully proves that the edaravone pharmaceutical composition of the present invention can completely replace the edaravone injection for use in clinical applications. Meanwhile, sublingual administration improves patient compliance and convenience of drug administration, greatly reducing emergency time and medical costs.

[0012] In the first aspect, the present invention provides a pharmaceutical composition comprising edaravone or a salt thereof as an active ingredient, a filler, a binder, and a disintegrant.

[0013] In one embodiment, the pharmaceutical composition is a sublingual preparation, for example, it may be in the form of tablets, films, flakes, gums, drops, powders or gels, etc., in particular, it may be sublingual tablets.

[0014] In another embodiment, the pharmaceutical composition does not comprise 2-camphanol, preferably does not comprise active ingredients other than edaravone or a salt thereof.

[0015] In one embodiment, the filler is not lactose, starch or microcrystalline cellulose, preferably the filler comprises mannitol, more preferably the filler is mannitol.

[0016] In one embodiment, in the pharmaceutical composition of the present invention, the mass ratio of edaravone or a salt thereof to the filler is 1:10 to 2:1, preferably 1:5 to 2:1, wherein when the edaravone salt is used as an active ingredient, the amount thereof is calculated based on edaravone (the same below).

[0017] In one embodiment, the filler accounts for 25% to 90%, 30% to 80%, 35% to 75%, 40% to 70%, 40% to 50% or 50% to 60% by mass of the pharmaceutical composition.

[0018] In one embodiment, the binder is not copovidone, preferably the binder comprises hydroxypropyl methylcellulose, more preferably the binder is hydroxypropyl methylcellulose.

5 **[0019]** In another embodiment, the disintegrant comprises at least one selected from the group consisting of croscarmellose sodium and crospovidone, preferably the disintegrant comprises crospovidone, more preferably the disintegrant is crospovidone.

[0020] In another embodiment, the pharmaceutical composition further comprises a lubricant, for example the lubricant comprises magnesium stearate, preferably the lubricant is magnesium
10 stearate.

[0021] In another embodiment, the pharmaceutical composition further comprises a glidant, for example the glidant comprises silica, preferably the glidant is silica.

[0022] In another embodiment, in the pharmaceutical composition of the present invention, the mass ratio of the filler: the binder: the disintegrant is (10 to 70):(0.5 to 15):(0.5 to 20) or (15 to
15 50):(1 to 8):(1 to 10).

[0023] In another embodiment, the pharmaceutical composition exists in a unit dosage form, wherein each unit dosage form of the pharmaceutical composition may contain 5 mg to 100 mg of edaravone or a salt thereof, or 10 mg to 80 mg, or 15 mg, 20 mg, 25 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, or a value between any two of the above. When the
20 edaravone salt is used as an active ingredient, the amount thereof is calculated based on edaravone (the same below).

[0024] In one embodiment, for sublingual preparations, a blood concentration of the edaravone reaches 10 to 10,000 ng/mL within 0.1 to 24 hours after sublingual administration to a patient in a unit dosage form..

25 **[0025]** In another embodiment, the pharmaceutical composition may also optionally comprise other pharmaceutically acceptable carriers such as lubricants, glidants, and/or flavoring agents in addition to the active ingredients, fillers, binders and disintegrants,.In particular, in addition to the

specific ingredients listed above, other ingredients that may function as fillers, binders, disintegrants, glidants, and/or lubricants can also be comprised, provided that their addition does not significantly affect the stability and/or release rate of the pharmaceutical composition of the present invention. Those skilled in the art can make selections according to actual needs. For example, suitable binders or excipients may also include, but are not limited to, cyclodextrin, ethyl cellulose, microcrystalline cellulose, dicalcium phosphate, calcium carbonate, silica, methyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose, alginate, gelatin, guar gum, tragacanth gum, gum arabic, polyacrylic acid, polymethacrylic acid, polysilicic acid and salts thereof, polylactic acid, polymaleic acid, polyvinyl alcohol, polyethylene glycol, polyvinylpyrrolidone, non-ionic block copolymer, carbomer, polycarbophil, polysorbate, water-soluble starch, and the like, or a combination thereof. Suitable lubricants can be selected from the group consisting of stearic acid, magnesium stearate, micronized silica gel, sodium stearyl fumarate, or a combination thereof. Suitable disintegrants can be selected from the group consisting of sodium carboxymethyl starch, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, or a combination thereof. Suitable flavoring agents can be selected from the group consisting of citric acid, acesulfame, aspartame, sucralose, and the like, or a combination thereof.

[0026] In another aspect, provided in the present invention are a method for the treatment and/or prevention of cerebrovascular disease and/or amyotrophic lateral sclerosis using the pharmaceutical composition, the pharmaceutical composition for use in the treatment and/or prevention of cerebrovascular disease and/or amyotrophic lateral sclerosis, and use of the pharmaceutical composition in the preparation of a medicament for the treatment and/or prevention of cerebrovascular disease and/or amyotrophic lateral sclerosis. In some embodiments, the cerebrovascular disease is ischemic cerebrovascular disease, such as stroke.

[0027] In another aspect, the pharmaceutical composition of the present invention can be prepared by mixing the active ingredient edaravone or a salt thereof with a suitable pharmaceutically acceptable carrier. In particular, for sublingual preparations, the following preparation methods can be adopted: mixing edaravone or a salt thereof with a suitable

pharmaceutically acceptable carrier, and compressing into tablets.

BRIEF DESCRIPTION OF DRAWINGS

5 [0028] Figure 1 is the dissolution profile of the sublingual tablets prepared according to Examples 1 to 5.

[0029] Figure 2 is the dissolution profile of the sublingual tablets prepared according to Examples 6 to 10.

[0030] Figure 3 is the dissolution profile of the sublingual tablets prepared according to Examples 11 to 14.

10

DETAILED DESCRIPTION

[0031] The present invention discloses an edaravone pharmaceutical composition, especially in a form of sublingual preparations. Those skilled in the art can achieve this by using the content of the present invention for reference, combining the principles of pharmacy, and appropriately
15 improving the process parameters or the formula ratio. It should be particularly pointed out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in the scope of the present invention. The applications of the present invention have been well described through the examples, and relevant personnel can make appropriate changes, alterations or combinations to the methods and applications described herein
20 without departing from the content, spirit and scope of the present invention to achieve and apply the present invention.

[0032] The following examples are used to further illustrate the present invention, but they are not meant to limit the protection scope of the present invention in any way.

[0033] The reagents and instruments used in the examples of the present disclosure are all
25 commercially available, and the bulk drugs and various excipients/additives, such as edaravone (Jiangsu Tiansheng Pharmaceutical Co., Ltd), lactose (FLOWLAC 100), microcrystalline cellulose (CEOLUS PH302), mannitol (Pearlitol 200SD), copovidone (PLASDONE S-630), hydroxypropyl

methylcellulose (SH-E5), croscarmellose sodium (AcDiSol), crospovidone (POLYPLASDONE XL-10), starch (tapioca starch), silica (Huzhou Zhanwang Pharmaceutical Co., Ltd.), magnesium stearate (Anhui Sunhere Pharmaceutical Excipients Co., Ltd.), are all in compliance with pharmaceutical standards.

5 Example 1

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Lactose	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Croscarmellose sodium	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0034] Preparation method: Edaravone, lactose, hydroxypropyl methylcellulose, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

10 Example 2

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Starch	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Croscarmellose sodium	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0035] Preparation method: Edaravone, starch, hydroxypropyl methylcellulose, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

Example 3

Material Name	Dosage per tablelet (mg)	Role
Edaravone	30	Active ingredient
Microcrystalline cellulose	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Croscarmellose sodium	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0036] Preparation method: Edaravone, microcrystalline cellulose, hydroxypropyl methylcellulose, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

Example 4

Material Name	Dosage per tablelet (mg)	Role
Edaravone	30	Active ingredient
Mannitol	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Croscarmellose sodium	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0037] Preparation method: Edaravone, mannitol, hydroxypropyl methylcellulose, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

Example 5

Material Name	Dosage per tablelet (mg)	Role
Edaravone	30	Active ingredient

Lactose	41.2	Filler
Copovidone	4	Binder
Croscarmellose sodium	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0038] Preparation method: Edaravone, lactose, copovidone, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

5 Example 6

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Microcrystalline cellulose	41.2	Filler
Copovidone	4	Binder
Croscarmellose sodium	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0039] Preparation method: Edaravone, microcrystalline cellulose, copovidone, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

10 Example 7

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Mannitol	41.2	Filler
Copovidone	4	Binder
Croscarmellose sodium	4	Disintegrant

Magnesium stearate	0.8	Lubricant
--------------------	-----	-----------

[0040] Preparation method: edaravone, mannitol, copovidone, croscarmellose sodium, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

5 Example 8

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Lactose	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Crospovidone	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0041] Preparation method: Edaravone, lactose, hydroxypropyl methylcellulose, crospovidone, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

10 Example 9

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Microcrystalline cellulose	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Crospovidone	4	Disintegrant
Magnesium stearate	0.8	Lubricant

[0042] Preparation method: Edaravone, microcrystalline cellulose, hydroxypropyl methylcellulose, crospovidone, and magnesium stearate were mixed uniformly according to the

formula ratio, and the mixture was compressed into tablets.

Example 10

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Mannitol	41.2	Filler
Hydroxypropyl methylcellulose	4	Binder
Crospovidone	4	Disintegrant
Magnesium stearate	0.8	Lubricant

5 **[0043]** Preparation method: edaravone, mannitol, hydroxypropyl methylcellulose, crospovidone and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

Example 11

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Mannitol	40.4	Filler
Hydroxypropyl methylcellulose	4	Binder
Crospovidone	4	Disintegrant
Silica	0.8	Glidant
Magnesium stearate	0.8	Lubricant

10 **[0044]** Preparation method: Edaravone, mannitol, hydroxypropyl methylcellulose, crospovidone, silica, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

Example 12

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Mannitol	15	Filler
Hydroxypropyl methylcellulose	2	Binder
Crospovidone	5	Disintegrant
Silica	0.5	Glidant
Magnesium stearate	0.5	Lubricant

[0045] Preparation method: Edaravone, mannitol, hydroxypropyl methylcellulose, crospovidone, silica, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

5 Example 13

Material Name	Dosage per tablet (mg)	Role
Edaravone	30	Active ingredient
Mannitol	30.2	Filler
Hydroxypropyl methylcellulose	1.4	Binder
Crospovidone	7	Disintegrant
Silica	0.7	Glidant
Magnesium stearate	0.7	Lubricant

[0046] Preparation method: Edaravone, mannitol, hydroxypropyl methylcellulose, crospovidone, silica, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

10 Example 14

Material Name	Dosage per tablet (mg)	Role
---------------	------------------------	------

Edaravone	30	Active ingredient
Mannitol	186	Filler
Hydroxypropyl methylcellulose	10	Binder
Crospovidone	20	Disintegrant
Silica	2	Glidant
Magnesium stearate	2	Lubricant

[0047] Preparation method: Edaravone, mannitol, hydroxypropyl methylcellulose, crospovidone, silica, and magnesium stearate were mixed uniformly according to the formula ratio, and the mixture was compressed into tablets.

5 Example 15

[0048] Stability test results: An appropriate amount of samples from Examples 1-14 were packaged in a simulated market packaging, and placed at a temperature of 40°C or 60°C for 10 days or 30 days for sampling. The characteristics, edaravone content, and related substances were determined and the results were shown in the following table:

Examples	Placing Conditions	Characteristics	Content (%)	Related Substances (%)
Example 1	0 day	White to off-white tablets	99.83	0.09
	40°C, 10 days	Light yellow tablets	99.64	0.13
	60°C, 10 days	Light yellow tablets	99.57	0.31
	40°C, 30 days	Light yellow tablets	98.48	0.76
	60°C, 30 days	Light yellow tablets	98.85	0.98
Example 2	0 day	White to off-white tablets	99.62	0.07

	40°C, 10 days	Light yellow tablets	99.75	0.21
	60°C, 10 days	Light yellow tablets	99.82	0.36
	40°C, 30 days	Light yellow tablets	98.64	0.84
	60°C, 30 days	Light yellow tablets	98.34	0.94
Example 3	0 day	White to off-white tablets	100.02	0.02
	40°C, 10 days	Light yellow tablets	100.04	0.16
	60°C, 10 days	Light yellow tablets	99.38	0.38
	40°C, 30 days	Light yellow tablets	98.56	0.72
	60°C, 30 days	Light yellow tablets	98.98	1.06
Example 4	0 day	White to off-white tablets	99.26	0.01
	40°C, 10 days	White to off-white tablets	99.75	0.05
	60°C, 10 days	White to off-white tablets	99.21	0.10
	40°C, 30 days	White to off-white tablets	99.25	0.43
	60°C, 30 days	White to off-white tablets	98.45	0.77
Example 5	0 day	White to off-white tablets	99.88	0.06
	40°C, 10 days	Light yellow tablets	99.27	0.23

	60°C, 10 days	Light yellow tablets	99.36	0.51
	40°C, 30 days	Light yellow tablets	98.25	1.01
	60°C, 30 days	Light yellow tablets	97.34	1.12
Example 6	0 day	White to off-white tablets	98.24	0.10
	40°C, 10 days	Light yellow tablets	98.65	0.21
	60°C, 10 days	Light yellow tablets	97.15	0.54
	40°C, 30 days	Light yellow tablets	98.12	1.02
	60°C, 30 days	Light yellow tablets	97.86	1.12
Example 7	0 day	White to off-white tablets	98.65	0.02
	40°C, 10 days	White to off-white tablets	100.42	0.08
	60°C, 10 days	White to off-white tablets	99.56	0.10
	40°C, 30 days	White to off-white tablets	98.89	0.43
	60°C, 30 days	White to off-white tablets	98.56	0.57
Example 8	0 day	White to off-white tablets	100.14	0.05
	40°C, 10 days	Light yellow tablets	100.23	0.13
	60°C, 10 days	Light yellow tablets	100.10	0.45
	40°C, 30 days	Light yellow	98.26	0.78

		tablets		
	60°C, 30 days	Light yellow tablets	98.84	0.95
Example 9	0 day	White to off-white tablets	99.58	0.08
	40°C, 10 days	Light yellow tablets	99.56	0.26
	60°C, 10 days	Light yellow tablets	99.84	0.46
	40°C, 30 days	Light yellow tablets	98.56	0.98
	60°C, 30 days	Light yellow tablets	98.87	1.12
Example 10	0 day	White to off-white tablets	99.52	0.01
	40°C, 10 days	White to off-white tablets	99.45	0.04
	60°C, 10 days	White to off-white tablets	99.36	0.12
	40°C, 30 days	White to off-white tablets	98.78	0.42
	60°C, 30 days	White to off-white tablets	98.85	0.63
Example 11	0 day	White to off-white tablets	99.18	0.02
	40°C, 10 days	White to off-white tablets	99.45	0.08
	60°C, 10 days	White to off-white tablets	99.25	0.16
	40°C, 30 days	White to off-white tablets	98.47	0.35

	60°C, 30 days	White to off-white tablets	98.36	0.75
Example 12	0 day	White to off-white tablets	99.58	0
	40°C, 10 days	White to off-white tablets	99.76	0.09
	60°C, 10 days	White to off-white tablets	99.85	0.21
	40°C, 30 days	White to off-white tablets	98.37	0.31
	60°C, 30 days	White to off-white tablets	98.21	0.76
Example 13	0 day	White to off-white tablets	100.49	0
	40°C, 10 days	White to off-white tablets	99.94	0.07
	60°C, 10 days	White to off-white tablets	98.26	0.18
	40°C, 30 days	White to off-white tablets	98.90	0.27
	60°C, 30 days	White to off-white tablets	98.40	0.81
Example 14	0 day	White to off-white tablets	99.86	0.02
	40°C, 10 days	White to off-white tablets	99.78	0.06
	60°C, 10 days	White to off-white tablets	99.85	0.15

	40°C, 30 days	White to off-white tablets	98.57	0.24
	60°C, 30 days	White to off-white tablets	98.46	0.91

[0049] According to the above table, the test results of Examples 1-14 showed that after being placed at a higher temperature for 30 days, the content of the active substance edaravone in all Examples 1-14 remained above 97%, which was satisfactory; the content of the active substance edaravone in most of the examples was kept above 98% except for a few examples (Examples 5 and 6). However, the inventors unexpectedly found that when lactose, starch or microcrystalline cellulose was selected as the filler in Examples 1-3, 5-6, and 8-9, color changes occurred on the appearance of the tablets when the tablets were placed at a higher temperature. On the contrary, in Examples 4, 7, and 10-14, when mannitol was used as the filler, the tablets maintained a high content of active ingredients and produced a very small amount of related substances during being placed at a higher temperature. Moreover, the properties were unchanged, all remaining white to off-white tablets, and the stability performance was particularly excellent.

Example 16

[0050] Test method for determination of dissolution: According to the determination method of the dissolution and release (*Chinese Pharmacopoeia* 2015, volume IV, 0931, second method), 900 ml of water was functioned as a dissolution medium, and the rotating speed was 50 rpm. Operations were performed according to said method. Samples were taken at different time points, filtered via a 0.8 μm filter membrane, and the subsequent filtrates were taken as the test solution; 20 mmol/L ammonium acetate/acetonitrile (80:20) was added to an appropriate amount of reference substance edaravone, and the edaravone was dissolved and diluted to approximately 0.02mg/ml for later use. The UV absorbance of the test solution was measured under the condition of 254 nm, and the dissolution rate of the samples was calculated. The results were shown in Figures 1, 2, and 3. The dissolution rate of examples 5, 6, and 7 which contains the adhesive copovidone was slower; the formulations of other examples had better dissolution results.

Example 17

Study on bridging PK of edaravone sublingual tablets and injections:

Materials and Methods

5 **[0051]** Experimental animals: Beagle dogs, male, weighing 8-10 kg; available from Beijing Marshall Biotechnology Co., Ltd.; certificate No.11400600012054; license No. SCXK (Beijing) 2016-0001.

[0052] Food and water supply: Animals were fasted for 12 hours before the test, and provided food 4 hours after administration. Animals received water ad libitum throughout the experiment. Abnormal reactions in animals were observed and recorded during drug administration and sample
10 collection.

[0053] Test drugs: Edaravone injection: specification: 10 mg/5 mL (Nanjing Simcere Pharmaceutical Co., Ltd.); sublingual tablets prepared according to the formula ratio of Example 5 (specification: 30 mg/tablet, tablet weight: 80 mg) ; sublingual tablets prepared according to the formula ratio of Example 7 (specification: 30 mg/tablet, tablet weight: 80 mg); sublingual tablets
15 prepared according to the formula ratio of Example 13 (specification: 30 mg/tablet, tablet weight: 70 mg); sublingual tablets prepared according to the formula ratio of Example 14 (specification: 30 mg/tablet, tablet weight: 250 mg).

[0054] Methods: The dogs were weighed on the day of the experiment, and the body weight of each dog was recorded for dripping or sublingual administration and calculation of related
20 pharmacokinetic parameters.

[0055] Group 1: Dripping administration of edaravone injection (N=2)

[0056] Dosage for administration: 12 mL, a total of 24 mg edaravone was administered.

[0057] The dogs were administered by intravenous dripping and dripping was ended after 12 minutes. The initiation time of dripping was regarded as the time point of 0 min, and then the whole
25 blood was collected at time points of 5 min, 12 min, 30 min, 45 min as well as 1, 1.5, 2, 3, 4, 6, 8, 10, and 24h.

[0058] Group 2: Sublingual administration of one sublingual tablet of Example 5 (N=3).

[0059] The Beagle dogs were administered sublingually by inserting the tablet under the tongue of the dogs at a dose of 1 tablet/dog with their mouth kept fixed for 12 minutes to prevent the tablet from falling out. Since involuntary saliva secretion and swallowing affect the efficacy of sublingual administration, their mouth needs to be fixed for 12 minutes. The time when the tablet was placed under the tongue was regarded as the time point of 0 min, and then the whole blood was collected at time points of 5 min, 12 min, 30 min, 45 min as well as 1, 1.5, 2, 3, 4, 6, 8, 10, and 24h.

[0060] Group 3: Sublingual administration of one sublingual tablet of Example 7 (N=3).

[0061] The Beagle dogs were administered sublingually by inserting the tablet under the tongue of the dogs at a dose of 1 tablet/dog with their mouth kept fixed for 12 minutes to prevent the tablet from falling out. Since involuntary saliva secretion and swallowing affect the efficacy of sublingual administration, their mouth needs to be fixed for 12 minutes. The time when the tablet was placed under the tongue was regarded as the time point of 0 min, and then the whole blood was collected at time points of 5 min, 12 min, 30 min, 45 min as well as 1, 1.5, 2, 3, 4, 6, 8, 10, and 24h.

[0062] Group 4: Sublingual administration of one sublingual tablet of Example 13 (N=3).

[0063] The Beagle dogs were administered sublingually by inserting the tablet under the tongue of the dogs at a dose of 1 tablet/dog with their mouth kept fixed for 12 minutes to prevent the tablet from falling out. Since involuntary saliva secretion and swallowing affect the efficacy of sublingual administration, their mouth needs to be fixed for 12 minutes. The time when the tablet was placed under the tongue was regarded as the time point of 0 min, and then the whole blood was collected at time points of 5 min, 12 min, 30 min, 45 min as well as 1, 1.5, 2, 3, 4, 6, 8, 10, and 24h.

[0064] Group 5: Sublingual administration of one sublingual tablet of Example 14 (N=3).

[0065] The Beagle dogs were administered sublingually by inserting the tablet under the tongue of the dogs at a dose of 1 tablet/dog with their mouth kept fixed for 12 minutes to prevent the tablet from falling out. Since involuntary saliva secretion and swallowing affect the efficacy of sublingual administration, their mouth needs to be fixed for 12 minutes. The time when the tablet was placed under the tongue was regarded as the time point of 0 min, and then the whole blood was collected

at time points of 5 min, 12 min, 30 min, 45 min as well as 1, 1.5, 2, 3, 4, 6, 8, 10, and 24h.

[0066] Experimental results: Each average pharmacokinetic parameter of edaravone in plasma after intravenous dripping of edaravone injection and sublingual administration of edaravone sublingual tablets in Beagle dogs.

5

	Intravenous injection	Example 5	Example 7	Example 13	Example 14
T_{max} (h)	0.50	0.75	0.67	0.63	0.50
C_{max} (ng/mL)	7195	5230	6029	8380	9580
AUC_{0-24h} (h*ng/mL)	12060	8115	9218	15693	12281
$AUC_{0-24h}/dose$ (ng·h·kg·mL ⁻¹ ·mg ⁻¹)	3934	2551	2880	4939	3934
MRT_{last} (h)	2.87	3.39	3.25	3.18	3.51
F (%)	/	64	73	125.5	100.0

[0067] The results of the PK bridging of the administration of sublingual tablets and injections for Beagle dogs showed that, for the edaravone sublingual preparations in Example 13 and in Example 14, edaravone was almost completely absorbed, meeting the conditions for sublingual administration. Edaravone sublingual tablets have advantages such as good pharmacokinetic properties, high bioavailability and convenient of use.

10

CLAIMS

1. A pharmaceutical composition comprising edaravone or a salt thereof as active ingredient, a filler, a binder and a disintegrant,

5 wherein the pharmaceutical composition is a sublingual tablet,

wherein the pharmaceutical composition does not comprise active ingredients other than edaravone or a salt thereof,

wherein the filler is mannitol,

wherein the binder is hydroxypropyl methylcellulose,

10 wherein the filler accounts for 25% to 90%, 30% to 80%, 35% to 75% or 40% to 70% by mass of the pharmaceutical composition, and

wherein the disintegrant is crospovidone.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical
15 composition further comprises a lubricant.

3. The pharmaceutical composition according to claim 2, wherein the lubricant comprises magnesium stearate.

20 4. The pharmaceutical composition according to claim 3, wherein the lubricant is magnesium stearate.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition further comprises a glidant.

25

6. The pharmaceutical composition according to claim 5, wherein the glidant comprises silica.

7. The pharmaceutical composition according to claim 6, wherein the glidant is silica.

5

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein a blood concentration of the edaravone reaches 10 to 10,000 ng/mL within 0.1 to 24 hours after sublingual administration to a patient in a unit dosage form.

10 9. Use of the pharmaceutical composition according to any one of claims 1 to 8 in the preparation of a medicament for the treatment and/or prevention of cerebrovascular disease.

10. The use according to claim 9, wherein the cerebrovascular disease is ischemic encephalopathy.

15

11. The use according to claim 10, wherein the cerebrovascular disease is stroke.

12. Use of the pharmaceutical composition according to any one of claims 1 to 8 for the treatment and/or prevention of cerebrovascular disease.

20

13. The use according to claim 12, wherein the cerebrovascular disease is ischemic encephalopathy.

14. The use according to claim 13, wherein the cerebrovascular disease is stroke.

15. Use of the pharmaceutical composition according to any one of claims 1 to 8 in the preparation of a medicament for the treatment and/or prevention of amyotrophic lateral sclerosis.

5 16. Use of the pharmaceutical composition according to any one of claims 1 to 8 for the treatment and/or prevention of amyotrophic lateral sclerosis.

DRAWINGS




Figure 1




Figure 2




Figure 3

Dissolution profile

